Immune Pharmaceuticals Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Immune Pharmaceuticals Inc. - overview
Location
New York, NY-New York, US
Primary Industry
Pharmaceuticals
About
Immune Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies targeting autoimmune diseases and cancer. Its strategic initiatives are aimed at enhancing treatment options and improving patient outcomes. Immune Pharmaceuticals specializes in the development of biopharmaceutical products for autoimmune disorders and oncology. The company was founded by Jean Kadouche.
Immune Pharmaceuticals is headquartered in New York, US. The company raised USD 11 mn in PIPE funding on November 17, 2016, marking its total amount raised to USD 11 mn across 4 deals. Immune Pharmaceuticals develops a range of biopharmaceutical products aimed at treating autoimmune diseases and cancer. The company emphasizes research and innovation to create effective treatment options that meet the needs of patients suffering from these conditions.
Its research focuses on novel therapies that target specific disease mechanisms, aiming to improve clinical outcomes. In the most recent year, 2017, Immune Pharmaceuticals reported zero revenue, with an EBITDA of USD -8. 82 mn. The company’s financial model is primarily based on developing and commercializing its therapeutic products in the biopharmaceutical market.
Immune Pharmaceuticals plans to utilize the USD 11 mn raised in its most recent PIPE funding to advance its research and development efforts. The company is focused on launching new therapeutic products targeting various autoimmune diseases and expanding its market presence in North America and Europe by 2018. These initiatives aim to enhance its product portfolio and improve access to innovative treatments for patients.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.immunepharma.com
Total Amount Raised
Subscriber access only
Immune Pharmaceuticals Inc. - financials
| Fiscal Year Ended | Dec 31, 2008 | Dec 31, 2009 | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 265,000 | 414,000 | 994,000 | 944,000 | 7,804,000 | 19,000 | 2,000 | - | - | - |
| % Revenue Growth (YoY) | - | 56.2% | 140.1% | (5.0%) | 726.7% | (99.8%) | (89.5%) | - | - | - |
| EBITDA (USD) | (21,289,000) | (7,861,000) | (15,053,000) | (13,026,000) | (61,000) | (8,692,000) | (15,990,000) | - | - | - |
| Operating Income (USD) | (21,957,000) | (18,737,000) | (15,374,000) | (14,053,000) | (606,000) | (9,000,000) | (16,363,000) | - | - | - |
| Operating Margin | (8285.7%) | (4525.8%) | (1546.7%) | (1488.7%) | (7.8%) | (47368.4%) | (818150.0%) | - | - | - |
| % EBITDA Margin | (8033.6%) | (1898.8%) | (1514.4%) | (1379.9%) | (0.8%) | (45747.4%) | (799500.0%) | - | - | - |
| NET Income (USD) | (25,382,000) | (38,814,000) | (15,537,000) | (15,656,000) | (2,573,000) | (5,760,000) | (23,550,000) | - | - | - |
| % Net Margin | (9578.1%) | (9375.4%) | (1563.1%) | (1658.5%) | (33.0%) | (30315.8%) | (1177500.0%) | - | - | - |
Immune Pharmaceuticals Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Immune Pharmaceuticals Inc. | - | ||||||||
| Venture Debt | Completed | Immune Pharmaceuticals Inc. | - | ||||||||
| PIPE | Completed | Immune Pharmaceuticals Inc. | - | ||||||||
| PIPE | Completed | Immune Pharmaceuticals Inc. | - |
Displaying 1 - 4 of 4
Immune Pharmaceuticals Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.